0RN4 Stock Chart & Stats
kr1.98
>-kr0.01(-0.37%)
At close: 4:00 PM EDT
kr1.98
>-kr0.01(-0.37%)
Day’s Range― - ―
52-Week Rangekr1.27 - kr6.14
Previous CloseN/A
Volume928.00
Average Volume (3M)37.87K
Market Cap
kr956.68M
Enterprise Valuekr595.78
Total Cash (Recent Filing)kr157.61M
Total Debt (Recent Filing)kr135.17M
Price to Earnings (P/E)―
Beta-0.01
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding381,148,130
10 Day Avg. Volume38,717
30 Day Avg. Volume37,872
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-18.53
Price to Sales (P/S)15.35
P/FCF Ratio-4.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)kr123.00M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And Strong Gross MarginRapid sales growth combined with a 98% gross margin indicates improving commercial adoption and attractive product economics. If this trajectory continues, higher revenue can absorb the existing cost base more effectively, support reinvestment, and move the company closer to sustainable operating cash generation.
European Market Potential And Long ExclusivityA sizeable European opportunity backed by exclusivity through 2037 provides a long runway for commercial development and reduces immediate competitive pressure on the product. This supports durable revenue potential, particularly as Oncopeptides expands prescribing and improves access across additional markets.
Central And Eastern Europe Partnership ExpansionThe Salus agreement expands Oncopeptides’ distribution reach without requiring the company to build a full commercial infrastructure in 11 countries. Slovenia has already secured a list price, while Croatia and the Czech Republic are next, creating a structured path to broader regional sales.
Bears Say
Substantial Cash Burn And Continuing LossesMaterial cash burn and deeply negative profitability mean the business has not yet converted strong gross margins into self-funded operations. Continued losses can consume liquidity and require additional financing before management’s target of positive cash flow during 2027 is achieved.
High Balance-Sheet LeverageDebt remains high relative to the equity base, limiting financial flexibility while the company is still loss-making. Elevated leverage increases reliance on successful commercial growth and may constrain investment or increase financing pressure if the path to cash-flow positivity takes longer than expected.
Delayed Japan Partnership And ExpansionFurther delays to the Japan partnership postpone potential geographic diversification and any associated licensing or commercial economics. Reopening discussions with other partners may extend the timeline, leaving near-term expansion more dependent on European execution and the existing Pepaxti markets.
Oncopeptides AB News
0RN4 FAQ
What was Oncopeptides AB’s price range in the past 12 months?
Oncopeptides AB lowest share price was kr1.27 and its highest was kr6.14 in the past 12 months.
What is Oncopeptides AB’s market cap?
Oncopeptides AB’s market cap is kr956.68M.
When is Oncopeptides AB’s upcoming earnings report date?
Oncopeptides AB’s upcoming earnings report date is Nov 05, 2026 which is in 41 days.
How were Oncopeptides AB’s earnings last quarter?
Oncopeptides AB released its earnings results on Aug 27, 2026. The company reported -kr0.144 earnings per share for the quarter.
Is Oncopeptides AB overvalued?
According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued.
Does Oncopeptides AB pay dividends?
Oncopeptides AB does not currently pay dividends.
What is Oncopeptides AB’s EPS estimate?
Oncopeptides AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncopeptides AB have?
Oncopeptides AB has 381,148,130 shares outstanding.
What happened to Oncopeptides AB’s price movement after its last earnings report?
Oncopeptides AB reported an EPS of -kr0.144 in its last earnings report. Following the earnings report the stock price went up 19.321%.
Which hedge fund is a major shareholder of Oncopeptides AB?
Currently, no hedge funds are holding shares in GB:0RN4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncopeptides AB
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
Technical Analysis
Alligator Bioscience AB
―
BioInvent International AB
―
Immunicum AB
―
Cantargia AB
―
Sprint Bioscience AB
―